This is certainly the big question, ie historical cash burn apprtox 1.5 mil a quarter yet last quarter was 3 mil and next quarter predicted 3 mil. Second last cr was rights issie at 1c then last effort was 4 mil at 4c, which was around market price at the time no discount so at that point very impressive.
We desperately need to know if cash burn will remain at 3 mil from here on or if the next quarter is expensive due to a huge push to get multiple deals over the line??
As always we have no real idea of the true level of intetest in our tech from pharma. Is anyone listerning at all, or are there multiple parties hanging on every word just waiting for that one test result that justifies pulling the trigger? There are always multiple interested parties in reports but lets face it none have come forward in last 3 years other than genentech.
PYC Price at posting:
2.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)